Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development

blonca9
Sep 12, 2024
1 min read

Danny Bar-Zohar describes Merck KGaA's three pillars of healthcare research: oncology, neurology, and immunology. Plus, the advantages of the company's heritageand location in Germany.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight